Qijie Xiaopi Decoction Attenuates Gastric Mucosal Injury in PLGC Rats by Inducing Autophagy and Apoptosis Through PI3K/AKT/mTOR Pathway Inhibition.
1/5 보강
[PURPOSE] Precancerous lesions of gastric cancer (PLGC) represent a crucial juncture in the transformation from gastritis to gastric cancer.
APA
Shan Y, Ma Y, et al. (2025). Qijie Xiaopi Decoction Attenuates Gastric Mucosal Injury in PLGC Rats by Inducing Autophagy and Apoptosis Through PI3K/AKT/mTOR Pathway Inhibition.. Journal of inflammation research, 18, 11979-11998. https://doi.org/10.2147/JIR.S532156
MLA
Shan Y, et al.. "Qijie Xiaopi Decoction Attenuates Gastric Mucosal Injury in PLGC Rats by Inducing Autophagy and Apoptosis Through PI3K/AKT/mTOR Pathway Inhibition.." Journal of inflammation research, vol. 18, 2025, pp. 11979-11998.
PMID
40917933 ↗
Abstract 한글 요약
[PURPOSE] Precancerous lesions of gastric cancer (PLGC) represent a crucial juncture in the transformation from gastritis to gastric cancer. Qijie Xiaopi Decoction (QJXPD), a Chinese herbal medicine formulation that has been applied in clinical practice to manage PLGC, which is capable of effectively relieving the symptoms experienced by patients such conditions. However, its mechanism of action remains unclear. The aim of this study is to elucidate the mechanism of action of QJXPD in the treatment of PLGC.
[METHODS] Ultra-high-performance liquid chromatography coupled with hybrid quadrupole-orbitrap tandem mass spectrometry (UHPLC-Q-Exactive Orbitrap-MS) was employed to pinpoint the chemical components of QJXPD. On this basis, network pharmacology and molecular docking were employed to pinpoint the main ingredients, probable targets, and associated pathways of QJXPD in treating of PLGC. A PLGC rat model was replicated using a compound modeling method mainly based on N-methyl-N'-nitro-N-nitrosoguanidine (MNNG), to observe the therapeutic effects of QJXPD on PLGC.
[RESULTS] The undiluted QJXPD solution contained 1069 compounds. Network pharmacology analysis revealed that QJXPD's anti-PLGC effects involved 119 active ingredients and 332 potential targets, primarily enriched in the PI3K/AKT pathway. Protein-protein interaction (PPI) analysis suggested that TP53, AKT1, SRC, STAT3, and EGFR were the key targets. Through molecular docking, it was discovered that the core targets exhibited a strong binding affinity with the primary active ingredients. Animal experiments have verified that QJXPD can significantly improve the general condition in PLGC rats, increase body weight, repair the damaged gastric mucosa and diminish the inflammatory infiltration, induce apoptosis of gastric mucosal cells, upregulate the expression of LC3, Beclin-1, and Bax and downregulate the expression of p62 and Bcl-2. The PI3K/AKT/mTOR pathway was inhibited by QJXPD.
[CONCLUSION] QJXPD effectively alleviated the pathological injury of gastric mucosa in PLGC rats by inhibiting the PI3K/AKT/mTOR signaling pathway and inducing cellular autophagy and apoptosis.
[METHODS] Ultra-high-performance liquid chromatography coupled with hybrid quadrupole-orbitrap tandem mass spectrometry (UHPLC-Q-Exactive Orbitrap-MS) was employed to pinpoint the chemical components of QJXPD. On this basis, network pharmacology and molecular docking were employed to pinpoint the main ingredients, probable targets, and associated pathways of QJXPD in treating of PLGC. A PLGC rat model was replicated using a compound modeling method mainly based on N-methyl-N'-nitro-N-nitrosoguanidine (MNNG), to observe the therapeutic effects of QJXPD on PLGC.
[RESULTS] The undiluted QJXPD solution contained 1069 compounds. Network pharmacology analysis revealed that QJXPD's anti-PLGC effects involved 119 active ingredients and 332 potential targets, primarily enriched in the PI3K/AKT pathway. Protein-protein interaction (PPI) analysis suggested that TP53, AKT1, SRC, STAT3, and EGFR were the key targets. Through molecular docking, it was discovered that the core targets exhibited a strong binding affinity with the primary active ingredients. Animal experiments have verified that QJXPD can significantly improve the general condition in PLGC rats, increase body weight, repair the damaged gastric mucosa and diminish the inflammatory infiltration, induce apoptosis of gastric mucosal cells, upregulate the expression of LC3, Beclin-1, and Bax and downregulate the expression of p62 and Bcl-2. The PI3K/AKT/mTOR pathway was inhibited by QJXPD.
[CONCLUSION] QJXPD effectively alleviated the pathological injury of gastric mucosa in PLGC rats by inhibiting the PI3K/AKT/mTOR signaling pathway and inducing cellular autophagy and apoptosis.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Sex-biased intratumoral microbiome influences tumor molecular and immune landscape and disease outcomes.
- A diagnostic model based on transcriptomic analysis reveals inflammation as a potential prognosis factor for hepatoblastoma with hepatocellular carcinoma features.
- Hyaluronic Acid Hydrogel Implants for Sustained Release of Oxaliplatin and Resiquimod to Prevent Hepatocellular Carcinoma Recurrence Post-Radiofrequency Ablation.
- Combined ultrasound endoscopy-guided fine-needle aspiration with DNA methylation of SHOX2 and RASSF1A genes to enhance the auxiliary diagnostic precision of pancreatic cancer.
- An autophagy-related lncRNA prognostic risk model for thyroid cancer.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- The role of disulfidptosis-driven tumor microenvironment remodeling in pancreatic cancer progression.
- A herbal formulation inhibits growth and survival of lung cancer cells through DNA damage and apoptosis - in vitro and in vivo studies.
- Mitocurcumin induces ROS-/JNK-mediated paraptosis to overcome chemoresistance in non-small cell lung cancer.
- Venetoclax induces mitochondrial apoptosis and autophagy to overcome arsenic trioxide resistance in acute promyelocytic leukemia.
- Risks, Benefits, and Molecular Targets of Fenugreek Administration in the Treatment of Hepatocellular Carcinoma.
- Dual-responsive semiconducting oligomer/doxorubicin nanoplatform for photoacoustic imaging-guided synergistic chemo-photothermal therapy.